Michael Burkes Brophy Sells 6,939 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 6,939 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $227.83, for a total value of $1,580,912.37. Following the transaction, the chief financial officer directly owned 52,120 shares in the company, valued at $11,874,499.60. This trade represents a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Thursday, January 29th, Michael Burkes Brophy sold 1,867 shares of Natera stock. The shares were sold at an average price of $230.40, for a total transaction of $430,156.80.
• On Wednesday, January 28th, Michael Burkes Brophy sold 2,413 shares of Natera stock. The shares were sold at an average price of $237.56, for a total transaction of $573,232.28.
• On Tuesday, January 27th, Michael Burkes Brophy sold 784 shares of Natera stock. The shares were sold at an average price of $240.53, for a total transaction of $188,575.52.
• On Wednesday, January 21st, Michael Burkes Brophy sold 37,175 shares of Natera stock. The shares were sold at an average price of $242.54, for a total transaction of $9,016,424.50.
• On Tuesday, January 20th, Michael Burkes Brophy sold 23,948 shares of Natera stock. The stock was sold at an average price of $234.74, for a total transaction of $5,621,553.52.

Natera Price Performance

Shares of NTRA stock opened at $197.08 on Friday. The company’s fifty day moving average price is $234.15 and its two-hundred day moving average price is $195.75. The firm has a market capitalization of $27.26 billion, a P/E ratio of -86.06 and a beta of 1.64. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $256.36.

Natera (NASDAQ:NTRA) last announced its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business had revenue of $592.18 million for the quarter, compared to analysts’ expectations of $514.55 million. During the same period in the previous year, the firm posted ($0.26) earnings per share. The firm’s revenue was up 34.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Regulatory/catalyst: Natera submitted a PMA to the FDA for Signatera CDx to detect minimal residual disease in bladder cancer after positive phase‑3 results — a potential pathway to a companion‑diagnostic revenue stream and better reimbursement/clinical adoption if approved. Natera files Signatera CDx PMA (Zacks)
• Neutral Sentiment: Routine insider trims: Several non‑executive insiders (e.g., Solomon Moshkevich, John Fesko) sold modest, single‑digit percentages of their positions; these look like routine liquidity actions but add incremental supply. InsiderTrades report on recent sales
• Negative Sentiment: Material CEO sale: CEO Steven Chapman sold 85,299 shares (~40% reduction) on Feb 2 for roughly $19.7M — a large, high‑visibility block that investors commonly view as a negative signal and that likely amplified downward pressure. CEO Form 4 (SEC)
• Negative Sentiment: Additional executive selling: CEO Chapman sold another 4,725 shares (Feb 3) and CFO Michael Burkes Brophy sold 6,939 shares (Feb 3), further trimming insider ownership and reinforcing near‑term selling pressure. CEO additional Form 4 CFO Form 4 (SEC)

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Wells Fargo & Company upped their target price on Natera from $190.00 to $205.00 and gave the company an “equal weight” rating in a research report on Monday, December 15th. BTIG Research upped their price target on shares of Natera from $230.00 to $260.00 and gave the company a “buy” rating in a report on Friday, December 5th. Citigroup began coverage on shares of Natera in a research note on Wednesday, January 7th. They set a “buy” rating and a $300.00 price objective on the stock. UBS Group boosted their target price on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Finally, BNP Paribas Exane upgraded shares of Natera to a “hold” rating and set a $172.00 target price on the stock in a research note on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $249.20.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Horizon Investments LLC bought a new stake in shares of Natera during the 3rd quarter valued at about $32,000. Hilltop National Bank bought a new position in Natera in the second quarter worth about $33,000. Sound Income Strategies LLC boosted its stake in Natera by 95.7% in the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 110 shares during the period. Flagship Harbor Advisors LLC bought a new position in shares of Natera during the fourth quarter valued at approximately $41,000. Finally, Quent Capital LLC acquired a new stake in shares of Natera during the 3rd quarter worth approximately $46,000. 99.90% of the stock is currently owned by institutional investors.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.